vasopressin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vasoconstrictors, vasopressin derivatives	2810	113-79-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vasopressin 8-L-arginine vasopressin synthetic vasopressin 8-L-Arginine-vasopressin argipressin vasopressin tannate vasopressin injection antidiuretic hormone pitressin tannate	Molecular weight: 1084.24 Formula: C46H65N15O12S2 CLOGP: -2.31 LIPINSKI: 3 HAC: 27 HDO: 15 TPSA: 461.43 ALOGS: -3.93 ROTB: 19 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vasopressin
8-L-arginine vasopressin
synthetic vasopressin
8-L-Arginine-vasopressin
argipressin
vasopressin tannate
vasopressin injection
antidiuretic hormone
pitressin tannate

Molecular weight: 1084.24
Formula: C46H65N15O12S2
CLOGP: -2.31
LIPINSKI: 3
HAC: 27
HDO: 15
TPSA: 461.43
ALOGS: -3.93
ROTB: 19

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
40	U	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI

Approvals:

Date	Agency	Company	Orphan
None	FDA	PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiogenic shock	168.61	37.67	57	3799	16268	56271943
Hypotension	150.03	37.67	129	3727	250379	56037832
Shock	134.61	37.67	52	3804	21676	56266535
Cardiac arrest	132.41	37.67	79	3777	86235	56201976
Drug ineffective	129.38	37.67	226	3630	918763	55369448
Septic shock	110.00	37.67	62	3794	60773	56227438
Intentional overdose	103.48	37.67	62	3794	68055	56220156
Metabolic acidosis	94.81	37.67	49	3807	40405	56247806
Multiple organ dysfunction syndrome	93.25	37.67	53	3803	52717	56235494
Vasoplegia syndrome	88.05	37.67	20	3836	1305	56286906
Pulseless electrical activity	86.37	37.67	28	3828	6996	56281215
Acute kidney injury	78.21	37.67	89	3767	240674	56047537
Toxicity to various agents	76.32	37.67	85	3771	224479	56063732
Lactic acidosis	69.21	37.67	38	3818	35308	56252903
Circulatory collapse	69.12	37.67	32	3824	20771	56267440
Local anaesthetic systemic toxicity	59.29	37.67	13	3843	721	56287490
Peripheral ischaemia	55.71	37.67	18	3838	4445	56283766
Disseminated intravascular coagulation	48.69	37.67	24	3832	17861	56270350
Diabetes insipidus	48.20	37.67	14	3842	2423	56285788
Hypothermia	47.15	37.67	21	3835	12449	56275762
Respiratory failure	44.85	37.67	43	3813	95019	56193192
Pulmonary oedema	44.63	37.67	33	3823	51110	56237101
Acute respiratory distress syndrome	38.61	37.67	22	3834	21904	56266307
Ventricular tachycardia	38.19	37.67	20	3836	16881	56271330
Haemodynamic instability	37.94	37.67	16	3840	8313	56279898

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiogenic shock	425.16	39.26	160	5915	22248	31669021
Appendicolith	412.73	39.26	113	5962	5618	31685651
Multiple organ dysfunction syndrome	364.32	39.26	201	5874	68002	31623267
Appendicitis	335.45	39.26	113	5962	11352	31679917
Stress	305.48	39.26	130	5945	24811	31666458
Ascites	215.98	39.26	120	5955	40893	31650376
Drug ineffective	198.39	39.26	304	5771	395269	31296000
Abdominal distension	187.35	39.26	118	5957	50566	31640703
Sepsis	175.22	39.26	178	5897	151751	31539518
Ventricular fibrillation	171.91	39.26	80	5995	18768	31672501
Hyponatraemia	158.16	39.26	123	5952	73676	31617593
General physical health deterioration	128.83	39.26	132	5943	113303	31577966
Diabetes insipidus	128.19	39.26	38	6037	2502	31688767
Vasoplegia syndrome	96.88	39.26	28	6047	1685	31689584
Abdominal pain	90.89	39.26	125	5950	145827	31545442
Constipation	89.20	39.26	114	5961	123877	31567392
Blood phosphorus increased	88.34	39.26	33	6042	4449	31686820
Shock	71.86	39.26	48	6027	22597	31668672
Hypotension	69.38	39.26	133	5942	204485	31486784
Off label use	58.79	39.26	172	5903	347102	31344167
Vomiting	54.27	39.26	127	5948	223846	31467423
Renal injury	52.70	39.26	30	6045	10635	31680634
Lactic acidosis	49.03	39.26	44	6031	31893	31659376
Cardiac arrest	48.96	39.26	72	6003	88990	31602279
Diarrhoea	44.98	39.26	7	6068	352402	31338867
Fatigue	44.30	39.26	6	6069	335200	31356069
Serotonin syndrome	43.80	39.26	33	6042	18740	31672529
Pulse absent	43.37	39.26	21	6054	5356	31685913
Septic shock	41.52	39.26	57	6018	66101	31625168
Metabolic acidosis	41.05	39.26	44	6031	39533	31651736
Respiratory failure	40.62	39.26	71	6004	101378	31589891
Compartment syndrome	39.61	39.26	16	6059	2655	31688614

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiogenic shock	581.64	29.03	211	9756	36096	70882381
Appendicolith	443.14	29.03	112	9855	5568	70912909
Multiple organ dysfunction syndrome	436.50	29.03	239	9728	108276	70810201
Appendicitis	323.67	29.03	112	9855	16621	70901856
Drug ineffective	304.72	29.03	500	9467	939252	69979225
Stress	222.33	29.03	131	9836	67835	70850642
Ascites	207.40	29.03	125	9842	67422	70851055
Sepsis	206.05	29.03	210	9757	244335	70674142
Ventricular fibrillation	195.62	29.03	89	9878	27022	70891455
Vasoplegia syndrome	191.56	29.03	51	9916	3105	70915372
Shock	181.51	29.03	96	9871	40329	70878148
Hypotension	176.10	29.03	248	9719	404133	70514344
Diabetes insipidus	171.78	29.03	51	9916	4620	70913857
Abdominal distension	145.05	29.03	119	9848	104550	70813927
Cardiac arrest	143.04	29.03	142	9825	159692	70758785
Hyponatraemia	128.25	29.03	134	9833	159953	70758524
Metabolic acidosis	123.31	29.03	94	9873	74252	70844225
Septic shock	114.04	29.03	107	9860	112151	70806326
Lactic acidosis	107.34	29.03	82	9885	64942	70853535
Intentional overdose	92.68	29.03	90	9877	98345	70820132
General physical health deterioration	92.47	29.03	138	9829	235893	70682584
Acute kidney injury	86.13	29.03	199	9768	474425	70444052
Blood phosphorus increased	85.03	29.03	33	9934	6737	70911740
Pulseless electrical activity	81.67	29.03	39	9928	13176	70905301
Respiratory failure	79.82	29.03	108	9859	168627	70749850
Fatigue	77.17	29.03	12	9955	824307	70094170
Toxicity to various agents	65.67	29.03	157	9810	382015	70536462
Haemodynamic instability	64.09	29.03	35	9932	15623	70902854
Peripheral ischaemia	60.76	29.03	28	9939	8730	70909747
Acute respiratory distress syndrome	59.35	29.03	48	9919	41206	70877271
Headache	57.65	29.03	7	9960	580398	70338079
Overdose	57.64	29.03	93	9874	169652	70748825
Off label use	56.85	29.03	230	9737	742830	70175647
Renal injury	55.10	29.03	32	9935	16062	70902415
Abdominal pain	54.94	29.03	137	9830	341990	70576487
Constipation	54.87	29.03	114	9853	252324	70666153
Circulatory collapse	54.71	29.03	43	9924	35431	70883046
Serotonin syndrome	54.33	29.03	46	9921	42068	70876409
Arthralgia	52.71	29.03	5	9962	503385	70415092
Dizziness	50.25	29.03	4	9963	464137	70454340
Pulse absent	50.04	29.03	25	9942	9305	70909172
Drug ineffective for unapproved indication	49.52	29.03	42	9925	38496	70879981
Local anaesthetic systemic toxicity	47.87	29.03	13	9954	852	70917625
Hyperdynamic left ventricle	47.87	29.03	11	9956	362	70918115
Distributive shock	43.31	29.03	15	9952	2222	70916255
Compartment syndrome	42.98	29.03	18	9949	4468	70914009
Rash	42.23	29.03	10	9957	510552	70407925
Bradycardia	40.54	29.03	67	9900	124548	70793929
Electrocardiogram QRS complex prolonged	40.35	29.03	22	9945	9784	70908693
Diarrhoea	40.11	29.03	31	9936	783310	70135167
Heparin-induced thrombocytopenia	39.21	29.03	21	9946	9016	70909461
Acidosis	39.14	29.03	27	9940	18236	70900241
Malaise	38.85	29.03	7	9960	432925	70485552
Dyspnoea	38.76	29.03	31	9936	770029	70148448
Renal failure	38.28	29.03	83	9884	188987	70729490
Disseminated intravascular coagulation	37.89	29.03	34	9933	33564	70884913
Dry gangrene	33.96	29.03	10	9957	879	70917598
Acute respiratory failure	32.68	29.03	39	9928	53626	70864851
Ventricular tachycardia	31.81	29.03	32	9935	36391	70882086
Fear	31.59	29.03	25	9942	20786	70897691
Renal tubular necrosis	31.30	29.03	26	9941	23145	70895332
Intestinal ischaemia	31.07	29.03	20	9947	12044	70906433
Ischaemic hepatitis	30.70	29.03	13	9954	3316	70915161
Anhedonia	30.42	29.03	21	9946	14192	70904285
Coma scale abnormal	30.08	29.03	17	9950	8099	70910378
Hypernatraemia	30.04	29.03	20	9947	12741	70905736
Asthenia	29.09	29.03	14	9953	457652	70460825

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01BA01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Vasopressin and analogues
FDA CS	M0022562	Vasopressins
FDA PE	N0000009908	Vasoconstriction
FDA PE	N0000175360	Decreased Diuresis
MeSH PA	D050034	Antidiuretic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D003029	Coagulants
MeSH PA	D006401	Hematologic Agents
MeSH PA	D006490	Hemostatics
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D014662	Vasoconstrictor Agents
CHEBI has role	CHEBI:35554	cardiovascular agent
CHEBI has role	CHEBI:50248	hematologic agents
CHEBI has role	CHEBI:52290	mitogens

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nocturnal enuresis	indication	8009008
Hereditary factor VIII deficiency disease	indication	28293008	DOID:12134
von Willebrand disorder	indication	128105004	DOID:12531
Partial Central Diabetes Insipidus	indication
Cardiac arrest	off-label use	410429000	DOID:0060319
Uremic Bleeding Tendency	off-label use
Chronic glomerulonephritis	contraindication	20917003
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Uremia	contraindication	44730006	DOID:4676
Heart failure	contraindication	84114007	DOID:6000
Epilepsy	contraindication	84757009	DOID:1826
Asthma	contraindication	195967001	DOID:2841
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.65	acidic
pKa2	12.19	acidic
pKa3	12.56	acidic
pKa4	12.85	acidic
pKa5	13.19	acidic
pKa6	13.43	acidic
pKa7	13.76	acidic
pKa8	10.75	Basic
pKa9	6.4	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9375478	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9687526	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9744209	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9744239	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	Dec. 17, 2016	RX	SOLUTION	INTRAVENOUS	9937223	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	10010575	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9925233	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9925234	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9962422	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9968649	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9974827	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 21, 2021	RX	SOLUTION	INTRAVENOUS	9981006	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 17, 2014	RX	SOLUTION	INTRAVENOUS	9375478	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 17, 2014	RX	SOLUTION	INTRAVENOUS	9687526	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 17, 2014	RX	SOLUTION	INTRAVENOUS	9744209	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 17, 2014	RX	SOLUTION	INTRAVENOUS	9744239	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	10010575	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9925233	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9925234	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9962422	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9968649	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9974827	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9981006	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	10010575	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9925233	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9925234	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9962422	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9968649	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9974827	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML)	VASOSTRICT	PAR STERILE PRODUCTS	N204485	April 15, 2020	RX	SOLUTION	INTRAVENOUS	9981006	Jan. 30, 2035	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
20UNITS/ML (20UNITS/ML)	VASOPRESSIN	EAGLE PHARMS	A211538	Dec. 15, 2021	RX	SOLUTION	INTRAVENOUS	July 17, 2022	PATENT CHALLENGE

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Vasopressin V1a receptor	GPCR	P37288	V1AR_HUMAN	AGONIST	Ki	9.59	CHEMBL	CHEMBL
Vasopressin V1b receptor	GPCR	P47901	V1BR_HUMAN	AGONIST	Ki	9.31	CHEMBL	CHEMBL
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN	AGONIST	Ki	8.92	CHEMBL	CHEMBL
Oxytocin receptor	GPCR	P30559	OXYR_HUMAN		Ki	8.78	CHEMBL
Vasopressin V2 receptor	GPCR		V2R_PIG		IC50	8.48	CHEMBL
Oxytocin receptor	GPCR		OXYR_RAT		Ki	8.93	CHEMBL
Vasopressin V2 receptor	GPCR		V2R_RAT		Ki	9.35	CHEMBL
Vasopressin V2 receptor	GPCR		V2R_BOVIN		Kd	8.82	CHEMBL
Vasopressin V1a receptor	GPCR		V1AR_RAT		Kd	9.19	CHEMBL
Vasopressin V1b receptor	GPCR		V1BR_RAT		Ki	9.54	CHEMBL
Vasopressin V1 receptor	GPCR		V1AR_RAT V1BR_RAT		Kd	9.19	CHEMBL

External reference:

ID	Source
4018654	VUID
N0000179795	NUI
D00101	KEGG_DRUG
4018654	VANDF
C1705480	UMLSCUI
CHEBI:9937	CHEBI
CHEMBL373742	ChEMBL_ID
CHEMBL2108986	ChEMBL_ID
DB00067	DRUGBANK_ID
2168	IUPHAR_LIGAND_ID
C016671	MESH_SUPPLEMENTAL_RECORD_UI
Y4907O6MFD	UNII
1098	RXNORM
3144	MMSL
5667	MMSL
d00398	MMSL
002122	NDDF
002123	NDDF
002126	NDDF
005438	NDDF
005439	NDDF
126192003	SNOMEDCT_US
421078009	SNOMEDCT_US
772208008	SNOMEDCT_US
77671006	SNOMEDCT_US
CHEMBL1201528	ChEMBL_ID
644077	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1020	INJECTION, SOLUTION	20 [USPU]	INTRAVENOUS	NDA	25 sections
Vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1020	INJECTION, SOLUTION	20 [USPU]	INTRAVENOUS	NDA	25 sections
Vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	0548-9701	INJECTION	20 [USPU]	INTRAVENOUS	ANDA	24 sections
VASOPRESSIN	HUMAN PRESCRIPTION DRUG LABEL	1	42367-570	INJECTION	20 U	PARENTERAL	ANDA	24 sections
vasopressin	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1642	INJECTION	20 [USPU]	INTRAVENOUS	ANDA	20 sections